| Document |
Document Title |
|
WO/2023/017400A1 |
Novel compounds of general Formula (I) derived from the conjugation of the native metformin drug to molecular moieties endowed with the property of releasing hydrogen sulfide are described. The compounds forming the object of the present...
|
|
WO/2023/011312A1 |
The present application belongs to the field of medicine, and discloses a multi-substituted thiazole derivative and an application thereof in disease treatment. Specifically, disclosed are a compound represented by formula I or a pharmac...
|
|
WO/2023/010051A1 |
The present invention features compounds useful in the inhibition of the secretion of proteins. The compounds of the invention can be used in methods for treating diseases associated with protein secretion, and in methods for inhibiting ...
|
|
WO/2023/009982A1 |
Disclosed are deubiquitinase (DUB) JOSD1 inhibitors and methods of treating a disease or disorder mediated by dysregulated Janus Kinase 2 (JAK2) activity, in a subject in need thereof, comprising administering a therapeutically effective...
|
|
WO/2023/004046A1 |
Disclosed herein are compounds that can be used to selectively detect superoxide in samples. Also disclosed herein are compositions comprising the compounds and methods of detecting superoxide using the compounds.
|
|
WO/2023/286057A1 |
Novel chemical compounds having herbicidal activity, agricultural compositions, process for their manufacture and their use in crop protection are provided.
|
|
WO/2023/275796A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combina...
|
|
WO/2022/268145A1 |
The present disclosure relates to an amide compound as represented by general formula I, or a prodrug, a pharmaceutically acceptable salt, a complex or a solvate thereof. The compound of the present disclosure has a new structure and has...
|
|
WO/2022/263800A1 |
The invention relates to a process for synthesising organic molecules. The invention provides a process for forming an sp2-sp3 carbon-carbon bond between a first compound comprising a substituted or unsubstituted aromatic group and a sec...
|
|
WO/2022/262657A1 |
The present invention relates to an N-substituted phenylsulfonamide compound and a use thereof. Specifically, the present invention provides a compound represented by formula I, or an optical isomer thereof, or a racemate thereof, or a p...
|
|
WO/2022/253645A1 |
A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.
|
|
WO/2022/255778A1 |
The present invention relates to a method for screening for a compound that binds to human IL-33 protein and inhibits IL-33, a composition for inhibiting IL-33 protein, comprising a compound selected through screening, and a pharmaceutic...
|
|
WO/2022/254034A1 |
The present invention concerns a compound having the formula (I), wherein: R1 is selected from the group consisting of: H, F, (C1-C6)alkoxy, and halo(C1-C6)alkyl; and R2 is an optionally substituted heteroaryl group, as well as processes...
|
|
WO/2022/245975A1 |
Caged luciferin-based probes become a luciferase substrate emitting bioluminescence upon β-lactamase/esterase activation. The inclusion of a cephalosporin moiety renders the probe capable of being used for the detection of a wide-range ...
|
|
WO/2022/245986A1 |
Compounds of the present application or pharmaceutically acceptable salts thereof are capable of interacting with and attenuating the activity of a stimulator of interferon genes (STING) protein. In an embodiment of the invention, inhibi...
|
|
WO/2022/238707A1 |
The present invention relates to a group of resorcinol derivatives as a pharmaceutically active compounds and methods of preparation thereof. Resorcinol derivatives have been used to treat various diseases and disorders. While such treat...
|
|
WO/2022/237780A1 |
An amide derivative and the pharmaceutical use thereof, in particular, the present invention relates to an amide derivative of formula (I) or a pharmaceutically acceptable salt thereof or all stereoisomers, tautomers and deuterated compo...
|
|
WO/2022/240213A1 |
The present invention relates to a novel benzothiazole derivative, a preparation method therefor, and a use thereof for preventing or treating liver diseases.
|
|
WO/2022/237782A1 |
Provided are an amide derivative of formula (I), or a pharmaceutically acceptable salt thereof, or all stereoisomers, tautomers, and deuterated products thereof, and a pharmaceutical composition comprising the compound. The compound or c...
|
|
WO/2022/232919A1 |
The present application relates to compounds, and uses thereof for example for preventing, delaying the onset or reducing the severity of, preventing or reversing the progression of, or treating a viral infection or disease. In an embodi...
|
|
WO/2022/218239A1 |
A new-type thiazole compound and a prodrug, a pharmaceutically acceptable salt, and a crystal thereof, a pharmaceutical composition of the prodrug, salt, and crystal, and a preparation method therefor and the use thereof. The compound ca...
|
|
WO/2022/219123A1 |
The present invention relates to ureal derivatives of formula (I) and pharmaceutical compositions comprising such derivatives for use in the treatment of uveal melanoma.
|
|
WO/2022/189856A9 |
This invention provides compounds, for example, of Formulae (A)-(H) and (J)-(AA) and pharmaceutically acceptable salts, solvates, esters, amides, and prodrugs thereof. The invention further provides pharmaceutical compositions comprising...
|
|
WO/2022/213935A1 |
Provided is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound can be used in the preparation of a drug for treating 1-sphingosine phosphate receptor 1-related diseases, such as autoimmun...
|
|
WO/2022/216627A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
|
WO/2022/216750A1 |
Provided herein are opioid receptor modulators and pharmaceutical compositions comprising said compounds.
|
|
WO/2022/214691A1 |
The invention relates to novel deuterated compounds of Formula (I) and their use as medicaments.
|
|
WO/2022/211520A1 |
The present invention relates to a novel compound and a use thereof for treatment of autoimmune disease. A pharmaceutical composition for treatment or prevention of autoimmune disease, comprising the novel compound of the present inventi...
|
|
WO/2022/206084A1 |
A thiazole compound represented by general formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, and a use thereof as a STAT3 pathway inhibitor. The compound has strong inhibitory activity on the proliferation o...
|
|
WO/2022/206725A1 |
Compounds of general Formula I, II, III, IV, V and their pharmaceutically acceptable salts, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are synthesis, ...
|
|
WO/2022/203246A1 |
The present specification relates to a compound represented by chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2022/200344A1 |
The present invention relates to a catalytic process for preparing 2-(phenylimino)-1,3-thiazolidine-4-one-sulfoxide derivatives of formula (I) in an enantiomerically pure or enantiomerically enriched form (I), wherein Y1, Y2, R1, R2 and ...
|
|
WO/2022/204080A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
|
WO/2022/193187A1 |
Compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating diseases, disorders of conditions mediated by the signaling of formyl peptide receptor 1 (FPR1).
|
|
WO/2022/194240A1 |
Compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating diseases, disorders of conditions mediated by the signaling of formyl peptide receptor 1 (FPR1).
|
|
WO/2022/191312A1 |
[Abstract] [Problem] To provide a method for producing a dealkoxyphenylation product with high yield from a substrate, e.g., a sugar, which is bonded to an alkoxyphenyl group through an oxygen atom. [Solution] A substrate that is bonded ...
|
|
WO/2022/184995A1 |
The invention relates to monomers which contain a 4-thiazolidinone unit linked to a benzene ring and which contain a meth(acrylate) function, a method for the synthesis thereof, and the use of same in the radical synthesis of polymers.
|
|
WO/2022/185241A1 |
The present invention provides a process of synthesizing 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-(
(2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)eth
ylidene)amino)oxy)cyclopropanecarboxylic acid, including a...
|
|
WO/2022/184994A1 |
The invention relates to monomers which contain a 4-thiazolidinone unit connected to a benzene core and which contain two functions selected from hydroxyl and carboxyl functions, and the method for synthesising same and the use thereof i...
|
|
WO/2022/183281A1 |
Among other things, in general, compositions and methods of treatment for muscular dystrophy and other diseases are disclosed. A method of treatment of a subject is disclosed, in which fatty acid utilization is improved. The method inclu...
|
|
WO/2022/182152A1 |
The present specification relates to: a compound represented by chemical formula 1 or 2; and an organic light emitting device comprising a first electrode, a second electrode, and one or more organic layers provided between the first ele...
|
|
WO/2022/181793A1 |
The present invention provides: a compound that is represented by formula (1) (in the formula, the combination of X and L represents a combination or the like in which X is a nitrogen atom and L is an oxygen atom or NH, n represents 1 or...
|
|
WO/2022/179211A1 |
Provided is a compound represented by formula (I). The compound can effectively inhibit the growth of clostridium difficile; and compared with nitazoxanide and other antibiotics, the compound also has significantly less influence on inte...
|
|
WO/2022/178736A1 |
Disclosed is a method for preparing a biphenyl benzothiazole compound. According to the present invention, a biphenyl benzothiazole compound is prepared by using N-(2-bromophenyl)alkylthioamides such as an N-(2-bromophenyl)alkylthioamide...
|
|
WO/2022/178693A1 |
A method for preparing a benzothiazole compound by using N-(2-bromophenyl)thioamide under promotion of visible light, comprising: under the protection of inert gas, adding reactants, N-(2-bromophenyl)thioamide and an inorganic base, into...
|
|
WO/2022/178694A1 |
Disclosed is a method for preparing an alkylbenzothiazole derivative under visible light, specifically comprising: under the protection of inert gas, adding N-(2-bromophenyl) alkyl thioamide and an inorganic alkali to a reaction vessel p...
|
|
WO/2022/181621A1 |
A condensed heterocyclic compound–containing composition comprising: a compound represented by general formula (A); and at least one compound selected from the group consisting of specific condensed heterocyclic compounds, specific aro...
|
|
WO/2022/175660A1 |
There are provided compounds of formula (I): [hyaluronan production inhibitor]—[labile linker]—X (I), which compounds are useful in the treatment of diseases associated with hyaluronan overproduction.
|
|
WO/2022/172786A1 |
Provided is a compound, represented by formula (1) below, useful for treating cancer or the like. In the formula, R1 and R3-R8 each independently indicate a hydrogen atom or an alkyl group. R2 indicates a hydrogen atom or a group represe...
|
|
WO/2022/172994A1 |
The present invention provides a method for producing an oligonucleotide having a phosphate ester bond by oxidizing an oligonucleotide precursor having a phosphite ester bond or a phosphonic acid ester bond via an oxidizing agent, wherei...
|
